Is intraprocedural intravenous aspirin safe for patients who require emergent extracranial stenting during mechanical thrombectomy?

Adam Ingleton, Marko Raseta, Rui-En Chung, Kevin Jun Hui Kow, Jake Weddell, Sanjeev Nayak, Changlez Jadun, Zafar Hashim, Noman Qayyum, Phillip Ferdinand, Indira Natarajan, Christine Roffe

ABSTRACT

Background Intraoperative antiplatelet therapy is recommended for emergent stenting during mechanical thrombectomy (MT). Most patients undergoing MT are also given thrombolysis. Antiplatelet agents are contraindicated within 24 hours of thrombolysis. We evaluated outcomes and complications of patients stented with and without intravenous aspirin during MT.

Methods All patients who underwent emergent extracranial stenting during MT at the Royal Stoke University Hospital, UK between 2010 and 2020, were included. Patients were thrombolysed before MT, unless contraindicated. Aspirin 500 mg intravenously was given intraoperatively at the discretion of the operator. Symptomatic intracranial haemorrhage (sICH) and the National Institutes for Health Stroke Scale score (NIHSS) were recorded at 7 days, and mortality and functional recovery (modified Rankin Scale: mRS ≤2) at 90 days.

Results Out of 565 patients treated by MT 102 patients (median age 67 IQR 57–72 years, baseline median NIHSS 18 IQR 13–23, 76 (75%) thrombolysed) had a stent placed. Of these 49 (48%) were given aspirin and 53 (52%) were not. Patients treated with aspirin had greater NIHSS improvement (median 8 IQR 1–16 vs median 3 IQR −9–8 points, p=0.003), but there were no significant differences in sICH (2/49 (4%) vs 9/53 (17%), mRS ≤2 (25/49 (51%) vs 19/53 (36%)) and mortality (10/49 (20%) vs 12/53 (23%)) with and without aspirin. NIHSS improvement (median 12 IQR 4–18 vs median 7 IQR −7–10, p=0.01) was greater, and mortality was lower (4/33 (12%) vs 6/15 (40%), p=0.05) when aspirin was combined with thrombolysis, than for aspirin alone, with no increase in bleeding.

Conclusion Our findings based on registry data derived from routine clinical care suggest that intraprocedural intravenous aspirin in patients undergoing emergent stenting during MT does not increase sICH and is associated with good clinical outcomes, even when combined with intravenous thrombolysis.

BACKGROUND

Endovascular treatment improves outcomes in patients with intracranial large artery occlusion. Emergent intraprocedural stenting of extracranial or intracranial arteries is often necessary to overcome an atherosclerotic plaque or thrombus and to provide access, maintain sufficient flow and prevent reoclusion. Most stents are placed in the carotid artery, but smaller intracranial and extracranial arteries are also included in some series.

Bridging therapy with intravenous alteplase prior to thrombectomy is given in most patients undergoing emergent or rescue stenting. Intravenous heparin is administered throughout the procedure to flush the lines and contributes to haemorrhage risk. Antiplatelet agents are required intraoperatively to ensure patency of the stent. However, there is evidence of increased haemorrhage risk if given concurrently with alteplase.
The European Stroke Organization Guidelines for intravenous thrombolysis after stroke state that antiplatelet agents should not be given within 24 hours after thrombolysis.13 There are no randomised controlled trials to guide antiplatelet management for emergent stenting, and practice varies.7, 14 While there is consensus among interventional neuroradiologists that intraoperative antiplatelets are required for emergent stenting,15 accepted practice among neuroradiologists is to avoid antiplatelets within 24 hours of thrombolysis.13

The aim of this study was to assess the safety, complications and outcomes of intraoperative intravenous aspirin during mechanical thrombectomy with emergent stenting in patients with and without thrombolysis before the procedure.

METHODS

All patients treated with mechanical thrombectomy for a large vessel occlusive stroke between January 2010 and December 2020 at the Royal Stoke University Hospital, a large comprehensive stroke centre in the UK were included. Data were extracted from a prospective database of all patients who received mechanical thrombectomy. Patients who had an extracranial stent placed during the procedure were included in the analysis. Details of thrombectomy pathways and service configuration have previously been described.15 16 Standard treatment before thrombectomy included intravenous thrombolysis with alteplase 0.9 mg/kg body weight (up to 6 hours from onset for anterior circulation infarcts and up to 12 hours for posterior circulation infarcts), unless contraindicated (most commonly anticoagulation with warfarin and an INR >1.7).17 Indications for thrombectomy are shown in figure 1.

Thrombectomies were conducted using a Stentriever, aspiration or a combination of both. Heparin (1000 IU/L) was given as per standard protocol to flush the catheters during the procedure. Emergent stenting was performed if necessary to achieve access to distal occlusions, if patency could not be maintained without a stent and if deemed technically feasible. The decision for stenting, additional treatment with angioplasty and use of intravenous aspirin during the procedure was at the discretion of the treating Interventional neuroradiologist. Use of aspirin reflected preferences of the operator and the treating stroke physician rather than differences in perceived bleeding risk. If antiplatelets were required intraoperatively, aspirin 500 mg intravenously was used. No other antiplatelet agents were used intraoperatively or postoperatively for the first 24 hours. Intraoperative aspirin was not given in patients who had a thrombectomy but were not stented. Once intracerebral haemorrhage was excluded at 24 hours using a CT head scan dual antiplatelet therapy (clopidogrel and aspirin) was given for 3 months, followed by long-term clopidogrel. Patients with minor asymptomatic haemorrhage (haemorrhagic transformation 1 (HT1) or 2 (HT2) or small subarachnoid haemorrhages) with good recanalisation were given aspirin 75 mg until clinically stable. In patients with clinically significant post-thrombectomy haemorrhage antiplatelet agents were delayed for a week or more at the discretion of the treating clinician. Functional outcome was assessed using the modified Rankin Scale (mRS) at 90 days over the phone or in person by a member of the stroke team not involved in the procedure. A good functional outcome was defined as an mRS of 0–2. For patients who were intubated or in coma, a National Institutes for Stroke Vasc Neurol: first published as 10.1136/svn-2022-002267 on 3 October 2023. Downloaded from http://svn.bmj.com/ on October 19, 2023 by guest. Protected by copyright.
### Table 1  Baseline demographics and clinical details

<table>
<thead>
<tr>
<th></th>
<th>All thrombectomies (n=565)</th>
<th>Thrombectomies with stenting (n=102)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) median (IQR)</td>
<td>67 (57–72)</td>
<td>68 (55–75)</td>
<td>0.004*</td>
</tr>
<tr>
<td>Male sex (n (%))</td>
<td>70 (69%)</td>
<td>27 (55%)</td>
<td>0.001†</td>
</tr>
<tr>
<td>Hypertension (n (%))</td>
<td>51 (50%)</td>
<td>21 (43%)</td>
<td>0.23†</td>
</tr>
<tr>
<td>Atrial fibrillation (n (%))</td>
<td>4 (4%)</td>
<td>2 (4%)</td>
<td>&lt;0.001†</td>
</tr>
<tr>
<td>Hyperlipidaemia (n (%))</td>
<td>27 (26%)</td>
<td>10 (20%)</td>
<td>0.27†</td>
</tr>
<tr>
<td>Diabetes (n (%))</td>
<td>18 (18%)</td>
<td>7 (14%)</td>
<td>0.63†</td>
</tr>
<tr>
<td>Previous stroke/TIA (n (%))</td>
<td>13 (13%)</td>
<td>7 (14%)</td>
<td>0.69†</td>
</tr>
<tr>
<td>Thrombolysis (n (%))</td>
<td>76 (75%)</td>
<td>34 (69%)</td>
<td>0.36†</td>
</tr>
<tr>
<td>NIHSS at baseline (median (IQR))</td>
<td>18 (13–23)</td>
<td>19 (15–23)</td>
<td>0.22*</td>
</tr>
<tr>
<td>Anterior circulation (n (%))</td>
<td>94 (92%)</td>
<td>45 (92%)</td>
<td>0.60†</td>
</tr>
<tr>
<td>Posterior circulation (n (%))</td>
<td>8 (8%)</td>
<td>4 (8%)</td>
<td>0.60†</td>
</tr>
<tr>
<td>Onset to groin time (min)</td>
<td>269 (195–343)</td>
<td>277 (204–359)</td>
<td>0.93*</td>
</tr>
<tr>
<td>Onset to lysis time (min)</td>
<td>123 (90–160)</td>
<td>115 (90–152)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Collateral score (n (%))</td>
<td>1†</td>
<td></td>
<td>0.11†</td>
</tr>
<tr>
<td>ASPECTS score</td>
<td>7 (6.75–9)</td>
<td>8 (6–9)</td>
<td>0.88*</td>
</tr>
</tbody>
</table>

*Mann-Whitney U test.
†Z-test.
‡Fisher’s exact test.

ASPECTS, The Alberta Stroke Programme Early CT Score; NIHSS, National Institutes for Health Stroke Scale score; TIA, Transient ischemic attack.
Table 2 Complications and outcomes in patients who were stented during thrombectomy with or without intraoperative aspirin

<table>
<thead>
<tr>
<th></th>
<th>All thrombectomies (n=565)</th>
<th>Thrombectomies with stenting (n=102)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stent (n=102)</td>
<td>No stent (n=463)</td>
</tr>
<tr>
<td>Thrombolysis in cerebral infarct score ≥2b (n (%))</td>
<td>92 (90%)</td>
<td>414 (90%)</td>
</tr>
<tr>
<td>NIHSS at 7 days median (IQR)</td>
<td>10 (3–20)</td>
<td>6 (2–16)</td>
</tr>
<tr>
<td>NIHSS difference baseline to 7 days median (IQR)</td>
<td>6 (-3–13)</td>
<td>9 (1–14)</td>
</tr>
<tr>
<td>Infarction at 24 hours (n (%))</td>
<td>79 (77%)</td>
<td>331 (72%)</td>
</tr>
<tr>
<td>Malignant middle cerebral artery syndrome (n (%))</td>
<td>6 (6%)</td>
<td>36 (8%)</td>
</tr>
<tr>
<td>Hemicraniectomy (n (%))</td>
<td>2 (2%)</td>
<td>9 (2%)</td>
</tr>
<tr>
<td>Symptomatic intracerebral haemorrhage (n (%))</td>
<td>11 (11%)</td>
<td>30 (7%)</td>
</tr>
<tr>
<td>Subarachnoid haemorrhage (n (%))</td>
<td>10 (10%)</td>
<td>42 (9%)</td>
</tr>
<tr>
<td>Stroke within 90 days (n (%))</td>
<td>0 (0.0%)</td>
<td>9 (2%)</td>
</tr>
<tr>
<td>Death at 90 days (n (%))</td>
<td>22 (22%)</td>
<td>76 (16%)</td>
</tr>
<tr>
<td>mRS 0–2 at 90 days (n (%))</td>
<td>44 (43%)</td>
<td>221 (48%)</td>
</tr>
</tbody>
</table>

*Z-test. †Mann-Whitney U test. ‡Fisher’s exact test. NIHSS, National Institutes for Health Stroke Scale score.

Health Stroke Scale score (NIHSS) of 35 was assigned. Death was recorded as a NIHSS of 42 and an mRS of 6.18

Successful recanalisation was defined by thrombolysis in cerebral infarct (TICI) score 2b-3. Symptomatic intracranial haemorrhage (sICH) was defined using Safe Implementation of Thrombolysis in Stroke Monitoring Study criteria,19 as a local or remote parenchymal haemorrhage type 2 on the 22–36 hour post-treatment head scan, combined with a neurological deterioration of four or more points from the lowest NIHSS within admission or leading to death. Malignant middle cerebral artery syndrome was defined as cerebral oedema causing midline shift with associated clinical deterioration of four or more NIHSS points.20

The Alberta Stroke Programme Early CT Score (ASPECTS) was determined retrospectively using RAPID software on existing CT head scans.21 Where this was not possible, scans were scored visually by two independent assessors. Collaterals were graded by the two independent assessors using single-phase CT angiogram collateral scoring,22 since perfusion imaging was not available in the first years of the study to allow collateral calculation.23

The study was reviewed by the Institutional Review Board at the Tertiary Centre and considered a service review analysing routinely collected data. Use of the registry data without individual informed consent was approved by the information governance team.

Statistical analysis

Data were summarised using medians, and percentages, where appropriate. Categorical variables were compared by means of Z-test (binary variables) and Fisher’s exact test (low expected per-cell observations). All continuous variables (age, onset to groin time, NIHSS at onset, 1 week and difference of the two) are reported as medians and IQRs and were compared by means of Mann-Whitney U-test. Moreover, ordinal numerical variable ASPECTS score was treated as a continuous variable in statistical analysis as it takes more than five different levels.24 Statistical analysis was done in R statistical software tool (R Core Team, 2018). Significance was accepted at p<0.05 level.

RESULTS

Demographics

A flow diagram showing patients who had thrombectomy, thrombolysis and aspirin is given in figure 1. In total, 565 thrombectomies were included. In 102 (18%), an emergent or rescue extracranial stent was placed (table 1). Stent patients were younger (median 67 vs median 70 years IQR 60–77, p=0.004), more likely to be men (69% vs 50%, p=0.001), less likely to have atrial fibrillation (4% vs 33%, p<0.001), and onset to lysis time was shorter (123 vs 135 min, p<0.001). There were no other significant differences between stented and non-stented patients. In the stented group, most strokes were severe (median NIHSS 18 (IQR 13–23) at baseline), affected the anterior circulation in 92%, and occurred in patients with multiple comorbidities.

Just under 50% of stented patients (n=49, 48%) were given intraoperative aspirin, with 53 (52%) patients not receiving aspirin during the procedure. The only significant difference in demographic and clinical characteristics between the patients given aspirin and those not given aspirin were more men (55% vs 81%, p=0.009) and shorter onset to lysis times (115 vs 123 min, p<0.001) for the aspirin group.
The majority of stented patients (n=76, 75%) were thrombolysed. Apart from age (62.0 vs 68.5 years, p=0.03) and male sex (79% vs 38%, p<0.001), there were no significant differences between thrombolysed and non-thrombolysed patients.

There were no differences in stroke severity (e.g., baseline NIHSS, infarct size on baseline CT head (ASPECTS) and collateral status) and delay between onset and the start of intervention (onset to groin time) between patients treated and not treated with aspirin and between patients thrombolysed and not thrombolysed.

Complications and outcomes in patients who were stented during thrombectomy

Outcomes and complications up to 90 days are shown in table 2. Procedural outcome was similar in patients who were stented to patients not requiring a stent with a high rate of successful recanalisation in both groups (90% TICI 2b or higher). While there was less reduction of neurological deficits at 1 week (median NIHSS difference from baseline 6 IQR –3–13 vs 9 IQR 1–14, p=0.02) in stented patients, longer term stroke recurrence, functional independence and mortality at 90 days were similar in both groups. Of those stented 11% had an sICH.

Complications and outcomes in relation to aspirin and thrombolysis

Table 3 compares patients who received aspirin with and without thrombolysis (n=34 and n=15, respectively) and those who received no aspirin during the procedure and did or did not get thrombolysis (n=42 and n=11, respectively). As these are further subgroups, numbers in each are small. Rate of successful recanalisation (97% vs 67% p=0.008), neurological recovery (NIHSS difference median 12 IQR 4–18 vs median 7 IQR –6–15, p=0.01) and mortality at 90 days (12% vs 40%, p=0.05) were significantly better when aspirin was combined with thrombolysis, than for aspirin alone, with no increase in bleeding.

For the group not given aspirin, outcomes are generally worse than for those given aspirin, with similar results in those thrombolysed and not thrombolysed. The only statistically significant difference in outcomes for this comparison was for sICH, which was more frequent in those given neither thrombolysis nor aspirin (n=5 (46%) vs n=4 (10%), p=0.01). The 34 patients who received both aspirin and thrombolysis had the lowest NIHSS at 1 week. This group also achieved the highest rate of functional independence at 90 days with 20 patients (59%) achieving an mRS≤2.

The number of stented patients over time span of this study is shown in online supplemental appendix.

### Table 3

<table>
<thead>
<tr>
<th>Complications and outcomes in stented patients in relation to aspirin and thrombolysis</th>
<th>Aspirin given intraoperatively (n=49)</th>
<th>No aspirin given intraoperatively (n=53)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Thrombolysed (n=34)</td>
<td>Not thrombolysed (n=15)</td>
</tr>
<tr>
<td>Thrombolysis in cerebral infarct score ≥2b (n (%))</td>
<td>33 (97%)</td>
<td>10 (67%)</td>
</tr>
<tr>
<td>NIHSS at 7 days median (IQR)</td>
<td>5 (2–14)</td>
<td>16 (2–36)</td>
</tr>
<tr>
<td>NIHSS difference baseline to 7 days median (IQR)</td>
<td>12 (4–18)</td>
<td>7 (-7–10)</td>
</tr>
<tr>
<td>Infarction at 24 hours (n (%))</td>
<td>26 (76%)</td>
<td>9 (60%)</td>
</tr>
<tr>
<td>Malignant middle cerebral artery syndrome (n (%))</td>
<td>0 (0%)</td>
<td>1 (7%)</td>
</tr>
<tr>
<td>Hemicraniectomy (n (%))</td>
<td>0 (0%)</td>
<td>1 (7%)</td>
</tr>
<tr>
<td>Symptomatic intracerebral haemorrhage (n (%))</td>
<td>1 (3%)</td>
<td>1 (6%)</td>
</tr>
<tr>
<td>Subarachnoid haemorrhage (n (%))</td>
<td>4 (12%)</td>
<td>2 (13%)</td>
</tr>
<tr>
<td>Stroke within 90 days (n (%))</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Death at 90 days (n (%))</td>
<td>4 (12%)</td>
<td>6 (40%)</td>
</tr>
<tr>
<td>mRS 0–2 at 90 days (n (%))</td>
<td>20 (59%)</td>
<td>5 (33%)</td>
</tr>
</tbody>
</table>

*Fisher’s exact test.
†Mann-Whitney U test.
‡Z-test.

mRS, modified Rankin Scale; NIHSS, National Institutes for Health Stroke Scale score.
Apart from the first 2 years, when only very few stents were placed, there is no clear trend in the proportion who received intraoperative intravenous aspirin (online supplemental appendix).

**DISCUSSION**

The main findings of this study are that neurological recovery at 1 week was significantly better in patients undergoing emergent stenting during mechanical thrombectomy given aspirin intraprocedurally than in those not receiving this treatment. At 90 days mortality was similar, with a weak trend towards better functional outcome with aspirin. Aspirin was not associated with an increase in intracerebral haemorrhage, whether given alone, or with intravenous thrombolysis.

The study population included all 102 patients treated with an emergent or rescue stent to an extracranial vessel representing 18% of patients treated by mechanical thrombectomy at our centre. As expected for patients with large-vessel stenosis, most strokes were severe (median NIHSS 18). Mortality was 22%, with the lowest rate (12%) in the subgroup receiving both thrombolysis and intraprocedural aspirin. This is similar to other studies examining emergent stenting with mortality ranging from 9.5% to 37.5%. Baseline NIHSS is a key determinant of mortality and functional outcome, and the results presented here reflect the higher baseline NIHSS (median 18) in our cohort than in cohort studies (medians 13–17) and meta-analyses (medians 13–17). Intraoperative aspirin did not affect functional independence at 90 days, with 43.0% achieving this in our study and 36%–57.9% in the other recent studies. Patients who received both thrombolysis and intraprocedural aspirin had the best outcomes with 12% mortality and 59% attaining functional independence at 90 days. While these outcomes could potentially have been confounded by more late presenters in those not given thrombolysis, our data show no significant differences in onset to groin time, baseline neurological deficit, infarct size on the CT head (ASPECTS) or collateral status for either the aspirin/no aspirin or the thrombolysis/no thrombolysis groups, suggesting major outcome predictors and bleeding risk were comparable. The results provide reassuring evidence that there are no major adverse interactions between thrombolysis and intravenous aspirin.

We found no excess of intracranial bleeding with aspirin or the combination of aspirin and thrombolysis, with haemorrhage rates. The rate of sICH among those who had thrombolysis and aspirin was 3%. A similarly low haemorrhage rate was reported in the TITAN registry, where the subgroup treated with thrombectomy, stent, antiplatelets and thrombolysis had an sICH haemorrhage rate of 2.4%. This contrasts with the findings of the ‘Antipla telet in combination with rtPA thrombolysis in Ischemic Stroke’ (ARTIS) trial in thrombolysed patients who did not undergo thrombectomy showed that the risk of sICH is significantly increased by giving aspirin intravenously within 90 min of thrombolysis, especially as the dose of intravenous aspirin given in this research study is 500 mg, this is higher than the 300 mg given in ARTIS. More recently the open-label MR CLEAN-MED study showed an increased risk of haemorrhage in patients given intraprocedural aspirin during mechanical thrombectomy. These studies provide evidence that giving aspirin soon after intravenous thrombolysis and/or during mechanical thrombectomy increases haemorrhage risk. This should be a reason to avoid aspirin soon after thrombolysis or during thrombectomy. However, neither has examined the effect in patients stented during thrombectomy, where intraoperative aspirin is part of routine care. Our study provides observational evidence to suggest that intraoperative aspirin may be safe even in the presence of thrombolysis in patients who require emergent stenting during mechanical thrombectomy.

In this study, we used aspirin 500 mg intravenously, as previously reported in a case series of emergent stenting during mechanical thrombectomy. A recent consensus statement by interventional neuroradiologists declared that aspirin should be used at a dose of 500 mg intravenously and also highlighted the lack of evidence to support this dose. The ARTIS RCT used aspirin 300 mg intravenously or no aspirin within 90 min of thrombolysis and reported an excess of intracranial haemorrhages. The same dose was used in the MR Clean MED thrombectomy RCT.

Neither of these studies examined outcomes in patients who were treated by emergent stenting. Table 4 shows that details of intraprocedural antiplatelet administration are poorly reported in studies and meta-analyses of emergent stenting, with aspirin 500 mg intravenously, cangrelor intravenously, dual antiplatelet therapy, tirofiban, GPIIb/IIIa inhibitors, heparin and abciximab used in different studies, while other studies provide no detail of antiplatelet therapy.

A major strength of this paper is the presentation of data from a single centre with consistent documentation of thrombolysis, use of a single antiplatelet regimen (intravenous aspirin) and the presence of a contemporaneous control group not given antiplatelets intraoperatively. Limitations of the study are that it is observational and that treatment with aspirin and thrombolysis was determined by the treating clinician rather than by chance, thus potentially introducing bias by indication. This could be particularly relevant for thrombolysis, where clear indications and contraindications exist, with patients not thrombolysed likely to have more complex comorbidities and presenting later. However, our data show no significant differences in comorbidities, baseline neurological deficit, extent of the infarct on CT, collateral status or onset to groin time between those thrombolysed and not thrombolysed.

As there is no definite evidence to guide aspirin use in this setting, choice of treatment was not systematic, but determined by clinical uncertainty, and this is confirmed by similar distributions of risks and outcome predictors
Table 4  Studies of emergent stenting during mechanical thrombectomy with details of the use of intraprocedural antiplatelet agents.

<table>
<thead>
<tr>
<th>Paper</th>
<th>Number stented/total cases</th>
<th>Indication</th>
<th>Centres</th>
<th>NIHSS before MT (median)</th>
<th>Territory</th>
<th>TICI ≥2</th>
<th>Key outcome mRS≤2</th>
<th>Symptomatic intracranial haemorrhage</th>
<th>Antiplaetelet choice</th>
<th>Thrombolysis</th>
<th>Mortality at 3 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Behme et al</td>
<td>170/170</td>
<td>ES</td>
<td>Multi (4)</td>
<td>15</td>
<td>Carotid</td>
<td>77%</td>
<td>36%</td>
<td>9%</td>
<td>Eptifibatide or tirofiban or aspirin 500 intravenous and clopidogrel via nasogastric tube</td>
<td>72%</td>
<td>19% (discharge)</td>
</tr>
<tr>
<td>Papanagiotou et al</td>
<td>322/482</td>
<td>ES</td>
<td>Multi</td>
<td>16</td>
<td>Carotid</td>
<td>81.1%</td>
<td>55.0%</td>
<td>7.1%</td>
<td>Variable intravenous aspirin, intravenous GP IIb/IIIa Inh, clopidogrel heparin</td>
<td>62%</td>
<td>11.2%</td>
</tr>
<tr>
<td>Zhu et al TITAN registry</td>
<td>256/295</td>
<td>ES</td>
<td>Multi</td>
<td>ND</td>
<td>Carotid</td>
<td>83.1%</td>
<td>57.9%</td>
<td>5.1%</td>
<td>All below</td>
<td>60%</td>
<td>9.5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4.4%</td>
<td>Antiplatelet and lysis (136)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8.6%</td>
<td>Antiplatelet alone (92)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>9.0%</td>
<td>Lysis alone (11)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0%</td>
<td>Neither (7)</td>
<td></td>
</tr>
<tr>
<td>Anadani et al TITAN Registry</td>
<td>205/205</td>
<td>ES</td>
<td>Multi</td>
<td>ND</td>
<td>Carotid</td>
<td>81%</td>
<td>56.6%</td>
<td>5.9%</td>
<td>Type of antiplatelet regime not reported</td>
<td>60%</td>
<td>12.7%</td>
</tr>
<tr>
<td>Hadler et al</td>
<td>73/548</td>
<td>xx</td>
<td>Single</td>
<td>xx</td>
<td>Carotid</td>
<td>40.6%</td>
<td>16%</td>
<td></td>
<td>Tirofiban, dual antiplatelet therapy</td>
<td>65.8%</td>
<td>28.1%</td>
</tr>
<tr>
<td>Chang et al</td>
<td>48/148</td>
<td>RS</td>
<td>Multi</td>
<td>14</td>
<td>Carotid, M1</td>
<td>64.8%</td>
<td>39.6%</td>
<td>16.7%</td>
<td>GP IIb/IIIa Inh and/or antiplatelets</td>
<td>46% intravenous, 15% ia</td>
<td></td>
</tr>
<tr>
<td>Stracke et al</td>
<td>210/210</td>
<td>RS</td>
<td>Multi</td>
<td>13</td>
<td>Any</td>
<td>82.9%</td>
<td>44.8%</td>
<td>10.5%</td>
<td>At least one agent, detail not fully reported</td>
<td>31%</td>
<td>18.5%</td>
</tr>
</tbody>
</table>

Continued
### Observational Studies

<table>
<thead>
<tr>
<th>Paper</th>
<th>Number stented/total cases</th>
<th>Indication</th>
<th>Centres</th>
<th>NIHSS before MT (median)</th>
<th>Territory</th>
<th>TICI ≥2</th>
<th>NICSSD intracranial haemorrhage</th>
<th>Antiplatelet choice</th>
<th>Thrombolysis</th>
<th>Mortality at 3 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delvoye et al</td>
<td>60/218</td>
<td>ES</td>
<td>Single</td>
<td>16</td>
<td>Carotid</td>
<td>ND</td>
<td>58.1%</td>
<td>Aspirin intravenous 250 mg (43) or abciximab 0.25 mg/kg (8)</td>
<td>53.5%</td>
<td>18.6%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12</td>
<td></td>
<td></td>
<td>37.5%</td>
<td>abciximab 0.25 mg/kg (8)</td>
<td>50.0%</td>
<td>37.5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17</td>
<td></td>
<td></td>
<td>33.3%</td>
<td>Bolus and infusion (9)</td>
<td>33.3%</td>
<td>11.1%</td>
</tr>
<tr>
<td>Peng et al</td>
<td>90/339</td>
<td>RS</td>
<td>Multi (16)</td>
<td>17</td>
<td>Anterior circulation</td>
<td>ND</td>
<td>36.4%</td>
<td>Tirofiban</td>
<td></td>
<td>31.9%</td>
</tr>
<tr>
<td>Schaefer et al</td>
<td>26/122</td>
<td>RS</td>
<td>Single</td>
<td>15*</td>
<td>ND</td>
<td>ND</td>
<td>3.6%</td>
<td>ND</td>
<td>39%</td>
<td>36% (discharge)</td>
</tr>
<tr>
<td>Mohamedan et al</td>
<td>107/499</td>
<td>RS</td>
<td>Multi (14)</td>
<td>16</td>
<td>Carotid</td>
<td>ND</td>
<td>34.6%</td>
<td>Not specified</td>
<td>29%</td>
<td>29.9%</td>
</tr>
<tr>
<td>Ingleton et al</td>
<td>102/565</td>
<td>RS</td>
<td>Single</td>
<td>18</td>
<td>Carotid, VA</td>
<td>90%</td>
<td>43%</td>
<td>All 102 (100%)</td>
<td>75%</td>
<td>22%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>19</td>
<td></td>
<td>88%</td>
<td>51%</td>
<td>Aspirin 500 mg intravenous in 49 (48%)</td>
<td>69%</td>
<td>20%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>18</td>
<td></td>
<td>92%</td>
<td>51%</td>
<td>No aspirin I in 53 (52%)</td>
<td>79%</td>
<td>23%</td>
</tr>
</tbody>
</table>

### Metanalyses and Systematic Reviews

<table>
<thead>
<tr>
<th>Paper</th>
<th>Number stented/total cases</th>
<th>Indication</th>
<th>Centres</th>
<th>NIHSS before MT (median)</th>
<th>Territory</th>
<th>TICI ≥2</th>
<th>NICSSD intracranial haemorrhage</th>
<th>Antiplatelet choice</th>
<th>Thrombolysis</th>
<th>Mortality at 3 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dufort et al</td>
<td>1635</td>
<td>ES</td>
<td>Meta-analysis of 16 studies</td>
<td>ND</td>
<td>Anterior circulation</td>
<td>ND</td>
<td>53.7%</td>
<td>Variable</td>
<td>Not specified</td>
<td>13.4%</td>
</tr>
<tr>
<td>Paul et al</td>
<td>129</td>
<td>ES</td>
<td>Pooled analysis</td>
<td>ND</td>
<td>Any</td>
<td>100%</td>
<td>ND</td>
<td>IV cangrelor</td>
<td>23.4%</td>
<td>ND</td>
</tr>
<tr>
<td>Sadegh-Gonik et al</td>
<td>338</td>
<td>ES</td>
<td>Meta-analysis of 14 studies</td>
<td>16*</td>
<td>Anterior circulation</td>
<td>76%</td>
<td>53%</td>
<td>Not specified</td>
<td>65%</td>
<td>14%</td>
</tr>
<tr>
<td>Maingard et al</td>
<td>365</td>
<td>RS</td>
<td>Meta-analysis of 12 studies</td>
<td>16*</td>
<td>Anterior circulation</td>
<td>35.7%</td>
<td>48.5%</td>
<td>Tirofiban, heparin, abciximab, aspirin, clopidogrel,</td>
<td>35.7%</td>
<td>21.9%</td>
</tr>
<tr>
<td>Sivan-Hoffman et al</td>
<td>193</td>
<td>ES</td>
<td>Meta-analysis of 11 studies 2010–2015</td>
<td>17*</td>
<td>Carotid</td>
<td>63.8%</td>
<td>44%</td>
<td>Not specified</td>
<td>54%</td>
<td>13%</td>
</tr>
</tbody>
</table>
CONCLUSION

The findings of our study based on registry data from routine clinical care suggest that intraprocedural intravenous administration of aspirin during mechanical thrombectomy is safe in patients undergoing emergent therapy during emergent stenting.

Despite the possibility of bias, as the study was non-randomised, there was no excess of intracranial haemorrhage, even when combined with intraprocedural therapeutic anticoagulation. Further research is needed to confirm our results, but given the current interventional practice is to administer antiplatelet therapy during emergent stenting, it is unlikely that operators would have sufficient equipoise to consider such a trial.
includes any translated material. BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access  This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID ID Adam Ingleton http://orcid.org/0000-0002-8151-9714

REFERENCES